Last reviewed · How we verify
levothyroxin
At a glance
| Generic name | levothyroxin |
|---|---|
| Also known as | L-T4, neonatal screening, Thyroxine, BC-T4CYS 150 µg tablet (Berlin-Chemie AG), Letrox® 150 µg tablet (Berlin-Chemie AG), |
| Sponsor | Ain Shams University |
| Target | THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Congenital hypothyroidism
- Diagnostic Test for Thyroid Dysfunction
- Goiter
- Hashimoto thyroiditis
- Hyperlipidemia
- Hypothyroidism
- Malignant tumor of thyroid gland
- Myxedema
Common side effects
- Tachycardia
- Palpitations
- Tremors
- Anxiety
- Nervousness
- Insomnia
- Headache
- Diarrhea
- Weight loss
- Heat intolerance
- Excessive sweating
- Increased appetite
Serious adverse events
- Myocardial infarction
- Cardiac arrest
- Heart failure
- Angina
- Arrhythmias
- Seizures
- Pseudotumor cerebri
- Slipped capital femoral epiphysis
- Craniosynostosis
- Angioedema
Key clinical trials
- Novel Approaches to the Treatment of Hypothyroidism (PHASE2, PHASE3)
- Comparison of Levothyroxine Formulations in the Treatment of Congenital Hypothyroidism
- Neuroendocrine Response in Pediatric Febrile Seizures
- T4/T3 Therapy in Hypothyroidism (PHASE2)
- SNUH Immune Checkpoint Inhibitor-induced Hypothyroidism Recovery Trial (NA)
- Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans (PHASE2)
- Dosing of LT4 in Older Individuals (PHASE4)
- A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- levothyroxin CI brief — competitive landscape report
- levothyroxin updates RSS · CI watch RSS
- Ain Shams University portfolio CI